Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Sheikh al-Hijri: Any person or entity that deviates from the unified position and communicates or agrees will expose itself to accountability without exception or leniency
Sheikh al-Hijri: There is no agreement, negotiation, or authorization with the armed gangs that falsely call themselves the government
Sheikh al-Hijri: We call on the remnant gang members to lay down their weapons and surrender
Hekmat al-Hijri: We consider continuing the defense and fight a national, humanitarian, and moral duty that cannot be compromised
Sheikh Hikmat al-Hijri: The spiritual leadership of the Druze community stresses the need to continue defending and fighting until the liberation of Sweida
IOF Northern Command chief Maj.-Gen. Uri Gordin: We are upping the pressure and the pace of attacks, and we will continue the attack in the southern Syrian region
IOF Northern Command chief Maj.-Gen. Uri Gordin: We are operating decisively in the Sweida region and attacking Syrian regime targets
Sheikh Youssef al-Jarbou: The complete integration of Sweida into the Syrian state and the affirmation of the full sovereignty of the Syrian state
Sheikh Youssef al-Jarbou: Respect the sanctity of homes and the lives of civilians and not harm any home or private property within the city
Sheikh Youssef Al-Jarbou: Hiring competent police officers and personnel from the Sweida Governorate to manage the security file in the governorate

New drug could stop breast cancer variant from returning by 25%

  • By Al Mayadeen English
  • Source: News Websites
  • 2 Jun 2023 18:15
4 Min Read

Thousands of women with the world's most prevalent form of breast cancer might benefit from a medicine that reduces their chances of relapse by a quarter.

  • x
  •  A radiologist uses a magnifying glass to check mammograms for breast cancer in Los Angeles, May 6, 2010 (AP Photo/Damian Dovarganes, File)
    A radiologist uses a magnifying glass to check mammograms for breast cancer in Los Angeles, May 6, 2010 (AP Photo/Damian Dovarganes, File)

Thousands more women with the world's most prevalent form of breast cancer might benefit from an innovative medicine that extends their lives and reduces their chances of relapse by a quarter.

Every year, more than 2 million women are diagnosed with the illness, which is the most common cancer in the world. Despite advances in treatment in recent decades, many individuals may experience cancer recurrence. If a recurrence occurs, it is usually at a later stage.

A promising study was revealed at the world's biggest cancer conference, the American Society of Clinical Oncology (Asco), indicating that ribociclib, a novel targeted treatment medicine, might be a game changer. According to trial data, it can improve survival and dramatically reduce the likelihood of cancer recurrence.

Ribociclib has previously been proven to improve survival in people with advanced breast cancer. However, researchers observed in a recent study that it may also improve outcomes for people with much earlier-stage illnesses, such as in the case where cancer has not yet reached lymph nodes.

The findings piqued the interest of researchers and oncologists at Asco's annual meeting in Chicago since the evidence shows that the medicine, also known as Kisqali, might prevent cancer from returning in a large population and influence global practice.

Ribociclib is a small molecule inhibitor, which is a type of targeted treatment. It acts by targeting CDK4 and CDK6 proteins in breast cancer cells, which regulate cell proliferation, including cancer cell growth.

The medicine reduced the chance of recurrence by 25% when administered in conjunction with normal hormone therapy compared to hormone therapy alone following traditional therapies, according to a late-stage experiment, and has been licensed by authorities in the UK and the US. 

Because of the large number of people it potentially aids, the earlier-stage setting, when tumors can still be surgically removed, is considered a far greater breakthrough.

Patients with breast cancer are often offered surgery, chemotherapy, or radiation treatment before being prescribed hormone-blocking medicines to try to prevent the illness from reoccurring.

Related News

Biden diagnosed with 'aggressive' prostate cancer

Senate report reveals Trump slashed cancer research by 31%

The study discovered that combining ribociclib with hormone treatment resulted in a "significant improvement" in disease-free survival durations for patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

Hormone receptor-positive, HER2-negative breast cancer is the most common subtype of the disease, making up nearly 70% of all breast cancer cases in the US.

According to lead author Dr. Dennis Slamon, “Currently, approved targeted treatments can only be used in a small population of patients diagnosed with hormone receptor-positive, HER2-negative early breast cancer, leaving many without an effective treatment option for reducing risk of the cancer returning."

Slamon explained that nearly one-third of people with stage two hormone receptor-positive HER2-negative will have a relapse after treatment and more than half with stage 3 will have the cancer make a full return.

“Thus, there is a significant unmet need for both reducing the risk of recurrence and providing a tolerable treatment option that keeps patients cancer-free without disrupting their daily life.”

The Natalee study involved 5,101 patients who were given either ribociclib for three years alongside five years of hormonal therapy or the hormonal therapy alone.

After three years, 90.4% of those taking ribociclib remained free of disease, compared with 87.1% in the hormonal therapy alone group. Ribociclib also showed more favorable outcomes in overall survival, recurrence-free survival, and distant disease-free survival, according to the researchers.

Dr. Rita Nanda, an Asco expert in Chicago, stated that the results suggest " there will be a role for adjuvant ribociclib for stage two and higher hormone receptor-positive, HER2-negative breast cancer,”

Dr Catherine Elliott, director of research and partnerships at Cancer Research UK called the findings "promising" although more research is needed.

“The combination of ribociclib and hormonal therapy could provide a new treatment option for people with this type of early-stage breast cancer, reducing the risk of the disease coming back and improving survival.”

  • Breast cancer
  • Cancer

Most Read

Yemen Navy sinks ETERNITY C ship, shares footage of operation

Yemen Navy sinks ETERNITY C ship, shares footage of operation

  • Politics
  • 9 Jul 2025
An Israeli soldier abandons an excavator during an ambush by al-Qassam Brigades. Arabic text reads "The moment the soldier fled", July, 10, 2025 (Al Qassam Military Media)

Israeli media rue al-Qassam footage, alarmed by fighters among troops

  • Politics
  • 11 Jul 2025
This satellite image from Planet Labs PBC shows damage after an Iranian attack at the al Udeid Airbase outside of Doha, Qatar, June 25, 2025 (Planet Labs PBC via AP)

Satellite images show Iran attack damaged US comms dome in Qatari base

  • Politics
  • 11 Jul 2025
Ukraine’s Corporate Carve-Up Collapses?

Ukraine’s Corporate Carve-Up Collapses?

  • Analysis
  • 11 Jul 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
Khamenei: Iran holds powerful strategic cards
Politics

Sayyed Khamenei: Iran holds powerful strategic cards

New cars are parked in the port of the southern city of Umm el Rashrash, near the border with Egypt, Occupied Palestine, February 15, 2012 (AFP)
Politics

Eilat Port shut down due to debts, Red Sea blockade

Smoke rises after and Israeli drone launched an airstrike on the entrance of the Syrian Ministry of Defense, Damascus, Syria, July, 16, 2025 (social media)
Politics

'Israel' hits Syrian military HQ in Damascus, strikes Sweida

China's Foreign Minister Wang Yi gestures to the media as he walks between meetings during the 58th ASEAN Foreign Ministers' meeting and related meetings at the Convention Centre in Kuala Lumpur Friday, July 11, 2025 (AP)
Politics

China backs Iran’s nuclear rights, calls for diplomacy over force

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS